3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Advanced or Metastatic Solid Tumors
2
Thymoma
1
Solid Tumor
1
Sarcoma
1
Piebaldism
1
Osteosarcoma
1
Nasopharyngeal Carcinoma
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumor
1
Advanced Renal Cell Carcinoma (aRCC)
1
Advanced Refractory Solid Tumors
1
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
envafolimab
×
1 year
×
Clear all
No trials found.